Choreo LLC Invests $256,000 in Doximity, Inc. (NASDAQ:DOCS)

Choreo LLC purchased a new position in shares of Doximity, Inc. (NASDAQ:DOCS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,782 shares of the company’s stock, valued at approximately $256,000.

A number of other hedge funds have also bought and sold shares of DOCS. Sanctuary Advisors LLC acquired a new stake in Doximity during the second quarter valued at approximately $270,000. Creative Planning raised its position in shares of Doximity by 13.7% during the 3rd quarter. Creative Planning now owns 22,104 shares of the company’s stock valued at $963,000 after acquiring an additional 2,671 shares in the last quarter. nVerses Capital LLC lifted its stake in Doximity by 67.5% during the third quarter. nVerses Capital LLC now owns 12,900 shares of the company’s stock worth $562,000 after purchasing an additional 5,200 shares during the last quarter. Bleakley Financial Group LLC acquired a new position in Doximity in the third quarter worth $213,000. Finally, Trust Point Inc. increased its stake in Doximity by 16.9% during the third quarter. Trust Point Inc. now owns 28,809 shares of the company’s stock valued at $1,255,000 after purchasing an additional 4,163 shares during the last quarter. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Timothy S. Cabral sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the completion of the sale, the director now directly owns 6,360 shares in the company, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 37.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on DOCS shares. Mizuho raised their price target on shares of Doximity from $55.00 to $65.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Canaccord Genuity Group downgraded Doximity from a “buy” rating to a “hold” rating and lifted their target price for the company from $40.00 to $60.00 in a research note on Wednesday, November 13th. KeyCorp lowered their target price on Doximity from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. JPMorgan Chase & Co. raised their price target on Doximity from $30.00 to $48.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Finally, Leerink Partnrs raised Doximity from a “hold” rating to a “strong-buy” rating in a research report on Friday, February 7th. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $64.22.

Doximity Stock Performance

Shares of DOCS stock opened at $77.13 on Friday. The stock has a market cap of $14.40 billion, a PE ratio of 77.13, a price-to-earnings-growth ratio of 4.61 and a beta of 1.39. The business’s fifty day moving average is $57.89 and its 200-day moving average is $47.37. Doximity, Inc. has a 1 year low of $22.96 and a 1 year high of $85.21.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.